Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia
Open Access
- 31 May 2012
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 119 (22), 5201-5210
- https://doi.org/10.1182/blood-2012-01-401687
Abstract
Whereas the improvement in outcome for children with acute lymphoblastic leukemia has been gratifying, the poor outcome of patients who relapse warrants novel treatment approaches. Previously, we identified a characteristic relapse-specific gene expression and methylation signature associated with chemoresistance using a large cohort of matched-diagnosis relapse samples. We hypothesized that “reversing” such a signature might restore chemosensitivity. In the present study, we demonstrate that the histone deacetylase inhibitor vorinostat not only reprograms the aberrant gene expression profile of relapsed blasts by epigenetic mechanisms, but is also synergistic when applied before chemotherapy in primary patient samples and leukemia cell lines. Furthermore, incorporation of the DNA methyltransferase inhibitor decitabine led to reexpression of genes shown to be preferentially methylated and silenced at relapse. Combination pretreatment with vorinostat and decitabine resulted in even greater cytotoxicity compared with each agent individually with chemotherapy. Our results indicate that acquisition of chemo-resistance at relapse may be driven in part by epigenetic mechanisms. Incorporation of these targeted epigenetic agents to the standard chemotherapy backbone is a promising approach to the treatment of relapsed pediatric acute lymphoblastic leukemia.Keywords
This publication has 50 references indexed in Scilit:
- HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLBlood, 2011
- Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 DemethylasesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group studyPediatric Blood & Cancer, 2010
- Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targetingBlood, 2010
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylationBlood, 2009
- Histone modification patterns and epigenetic codesBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Pro-proliferative FoxM1 is a target of p53-mediated repressionOncogene, 2009
- The Epigenomics of CancerCell, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Translating the Histone CodeScience, 2001